SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American ...
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation –
Source: eagletribune.com
Bernd Kasper News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bernd Kasper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bernd Kasper Today - Breaking & Trending Today
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in...
Source: marketscreener.com
FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment
Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.
Source: onclive.com
Dr Kasper on the FDA Approval of Nirogacestat in Desmoid Tumors
Bernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.
Source: onclive.com
Dr Kasper on the Evaluation of Nirogacestat in Desmoid Tumors in the DeFi Trial
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses the effect of nirogacestat on tumor volume and T2 hyperintensity in patients with desmoid tumors.
Source: onclive.com